Catalog Products » MonoRab™ Anti-Mosunetuzumab Antibody (38A10), mAb, Rabbit
MonoRab™ Anti-Mosunetuzumab Antibody (38A10), MAb, Rabbit

BLI (Biolayer interferometry) binding affinity measurements of MonoRab™ Anti-Mosunetuzumab Antibody (38A10), mAb, Rabbit (GenScript, A02291) to Mosunetuzumab and Cevostamab.
Mosunetuzumab captured on HFC (Anti-Human IgG Fc) Probes can bind MonoRab™ Anti-Mosunetuzumab Antibody (38A10), mAb, Rabbit with a dissociation constant (KD) of 7.51E-07M.
Cevostamab captured on HFC (Anti-Human IgG Fc) Probes can bind MonoRab™ Anti-Mosunetuzumab Antibody (38A10), mAb, Rabbit with a dissociation constant (KD) of 6.31E-10M.

MonoRab™ Anti-Mosunetuzumab Antibody (38A10), MAb, Rabbit

Left Figure: Anti-Mosunetuzumab Antibodies inhibit the binding of Mosunetuzumab to Human CD3 Epsilon. Coating antigen: Mosunetuzumab, 1 µg/mL.
Human CD3 Epsilon final concentration: 12.5 ng/mL.
Anti-Mosunetuzumab antibody dilutions start from 30 μg/mL.
MonoRab™ Anti-Mosunetuzumab Antibody (10D5), mAb, Rabbit (GenScript, A02292) exhibited non-inhibitory properties, whereas both MonoRab™ Anti-Mosunetuzumab Antibody (4G6), mAb, Rabbit (GenScript, A02290) and MonoRab™ Anti-Mosunetuzumab Antibody (38A10), mAb, Rabbit (GenScript, A02291) demonstrated significant inhibitory properties.

Right Figure: Anti-Mosunetuzumab Antibodies inhibit the binding of Cevostamab to Human CD3 Epsilon. Coating antigen: Cevostamab, 1 µg/mL.
Human CD3 Epsilon final concentration: 7 ng/mL.
Anti-Mosunetuzumab antibody dilutions start from 30 μg/mL.
MonoRab™ Anti-Mosunetuzumab Antibody (10D5), mAb, Rabbit (GenScript, A02292) exhibited non-inhibitory properties, whereas both MonoRab™ Anti-Mosunetuzumab Antibody (4G6), mAb, Rabbit (GenScript, A02290) and MonoRab™ Anti-Mosunetuzumab Antibody (38A10), mAb, Rabbit (GenScript, A02291) demonstrated significant inhibitory properties.

MonoRab™ Anti-Mosunetuzumab Antibody (38A10), MAb, Rabbit

Left Figure: Standard Curve of Mosunetuzumab Sandwich ELISA by A02290 (4G6) and A02291 (38A10)
In this Sandwich ELISA assay, MonoRab™ Anti-Mosunetuzumab Antibody (4G6), mAb, Rabbit (GenScript, A02290) was coated at a concentration of 1 μg/ml, and MonoRab™ Anti-Mosunetuzumab Antibody (38A10), mAb, Rabbit (GenScript, A02291) conjugated with Biotin was used as a detection antibody at a concentration of 0.4 μg/mL. GenScript can provide customized conjugation service for this product per customer's request. MRD was as 1:25.
In this assay, a four-parameter logistic curve fitting program was used to create a standard curve with the R-Square equal to 0.99981. The typicaldynamic range of the assay is 16 - 1,000 ng/mL. Right Figure: Standard Curve of Cevostamab Sandwich ELISA by A02290 (4G6) and A02291 (38A10)
In this Sandwich ELISA assay, MonoRab™ Anti-Mosunetuzumab Antibody (4G6), mAb, Rabbit (GenScript, A02290) was coated at a concentration of 1 μg/ml, and MonoRab™ Anti-Mosunetuzumab Antibody (38A10), mAb, Rabbit (GenScript, A02291) conjugated with Biotin was used as a detection antibody at a concentration of 0.4 μg/mL. GenScript can provide customized conjugation service for this product per customer's request. MRD was as 1:25.
In this assay, a four-parameter logistic curve fitting program was used to create a standard curve with the R-Square equal to 0.99993. The typicaldynamic range of the assay is 23 - 1,500 ng/mL.

MonoRab™ Anti-Mosunetuzumab Antibody (38A10), MAb, Rabbit

MRD Analysis of the Detection of Mosunetuzumab or Cevostamab in Biological Matrix.
The MRD is the minimum dilution necessary for the detection of Mosunetuzumab or Cevostamab in biological matrix with least interference. Serum samples from cynomolgus monkey were serially diluted to determine the MRD of this assay, and the test result suggested that MRD was as 1:25.
In this ELISA assay, MonoRab™ Anti-Mosunetuzumab Antibody (4G6), mAb, Rabbit (GenScript, A02290) was coated at a concentration of 1 μg/ml, and MonoRab™ Anti-Mosunetuzumab Antibody (38A10), mAb, Rabbit (GenScript, A02291) conjugated with Biotin was used as a detection antibody at a concentration of 0.4 μg/mL.

MonoRab™ Anti-Mosunetuzumab Antibody (38A10), MAb, Rabbit

Specificity analysis of the detection of Mosunetuzumab or Cevostamab.
Mosunetuzumab or Cevostamab samples at 7 concentrations were spiked with 10 μg/mL of human IgG1. The test result demonstrated that the high concentration of human IgG1 did not interfere with the detection of Mosunetuzumab or Cevostamab.
In this ELISA assay, MonoRab™ Anti-Mosunetuzumab Antibody (4G6), mAb, Rabbit (GenScript, A02290) was coated at a concentration of 1 μg/ml, and MonoRab™ Anti-Mosunetuzumab Antibody (38A10), mAb, Rabbit (GenScript, A02291) conjugated with Biotin was used as a detection antibody at a concentration of 0.4 μg/mL.

MonoRab™ Anti-Mosunetuzumab Antibody (38A10), mAb, Rabbit

This product is specific for Mosunetuzumab and Cevostamab.
A02291
$205.00

Ask us a question
Overview
Specificity This product is specific for Mosunetuzumab and Cevostamab.
Host Species Rabbit
Immunogen Mosunetuzumab
Conjugate Unconjugated

Applications
Working concentrations for specific applications should be determined by the investigators. The appropriate concentrations may be affected by secondary antibody affinity, antigen concentration, the sensitivity of the method of detection, temperature, the length of the incubations, and other factors. The suitability of this antibody for applications other than those listed below has not been determined. The following concentration ranges are recommended starting points for this product.
Application Recommended Usage
Sandwich ELISA 0.4-2 μg/ml
ELISA 0.01-1 µg/ml
Competitive ELISA 1-10 μg/ml

Properties
Form Lyophilized
Storage Buffer Lyophilized with PBS, pH 7.2, containing 0.02% sodium azide.
Reconstitution Reconstitute the lyophilized antibody with deionized water (or equivalent) to a final concentration of 0.5 mg/mL.
Storage Instructions The lyophilized product remains stable for up to 1 year at -20 °C from the date of receipt. Upon reconstitution, it can be stored for 2-3 weeks at 2-8 °C or for up to 12 months at -20 °C or below. Avoid repeated freezing and thawing cycles.
Purification Protein A affinity column
Isotype Rabbit IgG, κ
Clonality Monoclonal
Clone ID 38A10
Note GenScript can customize this product per customer's request including product size, buffer components, etc.

Examples
  • MonoRab™ Anti-Mosunetuzumab Antibody (38A10), MAb, Rabbit
  • MonoRab™ Anti-Mosunetuzumab Antibody (38A10), MAb, Rabbit

    BLI (Biolayer interferometry) binding affinity measurements of MonoRab™ Anti-Mosunetuzumab Antibody (38A10), mAb, Rabbit (GenScript, A02291) to Mosunetuzumab and Cevostamab.
    Mosunetuzumab captured on HFC (Anti-Human IgG Fc) Probes can bind MonoRab™ Anti-Mosunetuzumab Antibody (38A10), mAb, Rabbit with a dissociation constant (KD) of 7.51E-07M.
    Cevostamab captured on HFC (Anti-Human IgG Fc) Probes can bind MonoRab™ Anti-Mosunetuzumab Antibody (38A10), mAb, Rabbit with a dissociation constant (KD) of 6.31E-10M.

  • MonoRab™ Anti-Mosunetuzumab Antibody (38A10), MAb, Rabbit
  • MonoRab™ Anti-Mosunetuzumab Antibody (38A10), MAb, Rabbit

    Left Figure: Anti-Mosunetuzumab Antibodies inhibit the binding of Mosunetuzumab to Human CD3 Epsilon. Coating antigen: Mosunetuzumab, 1 µg/mL.
    Human CD3 Epsilon final concentration: 12.5 ng/mL.
    Anti-Mosunetuzumab antibody dilutions start from 30 μg/mL.
    MonoRab™ Anti-Mosunetuzumab Antibody (10D5), mAb, Rabbit (GenScript, A02292) exhibited non-inhibitory properties, whereas both MonoRab™ Anti-Mosunetuzumab Antibody (4G6), mAb, Rabbit (GenScript, A02290) and MonoRab™ Anti-Mosunetuzumab Antibody (38A10), mAb, Rabbit (GenScript, A02291) demonstrated significant inhibitory properties.

    Right Figure: Anti-Mosunetuzumab Antibodies inhibit the binding of Cevostamab to Human CD3 Epsilon. Coating antigen: Cevostamab, 1 µg/mL.
    Human CD3 Epsilon final concentration: 7 ng/mL.
    Anti-Mosunetuzumab antibody dilutions start from 30 μg/mL.
    MonoRab™ Anti-Mosunetuzumab Antibody (10D5), mAb, Rabbit (GenScript, A02292) exhibited non-inhibitory properties, whereas both MonoRab™ Anti-Mosunetuzumab Antibody (4G6), mAb, Rabbit (GenScript, A02290) and MonoRab™ Anti-Mosunetuzumab Antibody (38A10), mAb, Rabbit (GenScript, A02291) demonstrated significant inhibitory properties.

  • MonoRab™ Anti-Mosunetuzumab Antibody (38A10), MAb, Rabbit
  • MonoRab™ Anti-Mosunetuzumab Antibody (38A10), MAb, Rabbit

    Left Figure: Standard Curve of Mosunetuzumab Sandwich ELISA by A02290 (4G6) and A02291 (38A10)
    In this Sandwich ELISA assay, MonoRab™ Anti-Mosunetuzumab Antibody (4G6), mAb, Rabbit (GenScript, A02290) was coated at a concentration of 1 μg/ml, and MonoRab™ Anti-Mosunetuzumab Antibody (38A10), mAb, Rabbit (GenScript, A02291) conjugated with Biotin was used as a detection antibody at a concentration of 0.4 μg/mL. GenScript can provide customized conjugation service for this product per customer's request. MRD was as 1:25.
    In this assay, a four-parameter logistic curve fitting program was used to create a standard curve with the R-Square equal to 0.99981. The typicaldynamic range of the assay is 16 - 1,000 ng/mL. Right Figure: Standard Curve of Cevostamab Sandwich ELISA by A02290 (4G6) and A02291 (38A10)
    In this Sandwich ELISA assay, MonoRab™ Anti-Mosunetuzumab Antibody (4G6), mAb, Rabbit (GenScript, A02290) was coated at a concentration of 1 μg/ml, and MonoRab™ Anti-Mosunetuzumab Antibody (38A10), mAb, Rabbit (GenScript, A02291) conjugated with Biotin was used as a detection antibody at a concentration of 0.4 μg/mL. GenScript can provide customized conjugation service for this product per customer's request. MRD was as 1:25.
    In this assay, a four-parameter logistic curve fitting program was used to create a standard curve with the R-Square equal to 0.99993. The typicaldynamic range of the assay is 23 - 1,500 ng/mL.

  • MonoRab™ Anti-Mosunetuzumab Antibody (38A10), MAb, Rabbit
  • MonoRab™ Anti-Mosunetuzumab Antibody (38A10), MAb, Rabbit

    MRD Analysis of the Detection of Mosunetuzumab or Cevostamab in Biological Matrix.
    The MRD is the minimum dilution necessary for the detection of Mosunetuzumab or Cevostamab in biological matrix with least interference. Serum samples from cynomolgus monkey were serially diluted to determine the MRD of this assay, and the test result suggested that MRD was as 1:25.
    In this ELISA assay, MonoRab™ Anti-Mosunetuzumab Antibody (4G6), mAb, Rabbit (GenScript, A02290) was coated at a concentration of 1 μg/ml, and MonoRab™ Anti-Mosunetuzumab Antibody (38A10), mAb, Rabbit (GenScript, A02291) conjugated with Biotin was used as a detection antibody at a concentration of 0.4 μg/mL.

  • MonoRab™ Anti-Mosunetuzumab Antibody (38A10), MAb, Rabbit
  • MonoRab™ Anti-Mosunetuzumab Antibody (38A10), MAb, Rabbit

    Specificity analysis of the detection of Mosunetuzumab or Cevostamab.
    Mosunetuzumab or Cevostamab samples at 7 concentrations were spiked with 10 μg/mL of human IgG1. The test result demonstrated that the high concentration of human IgG1 did not interfere with the detection of Mosunetuzumab or Cevostamab.
    In this ELISA assay, MonoRab™ Anti-Mosunetuzumab Antibody (4G6), mAb, Rabbit (GenScript, A02290) was coated at a concentration of 1 μg/ml, and MonoRab™ Anti-Mosunetuzumab Antibody (38A10), mAb, Rabbit (GenScript, A02291) conjugated with Biotin was used as a detection antibody at a concentration of 0.4 μg/mL.


Background
Target Background Mosunetuzumab is an innovative bispecific antibody that has a structure that resembles a natural human antibody, with two 'Fab' regions. However, it differs from naturally-occurring antibodies as one 'Fab' region targets CD20 and the other targets CD3. By recognizing and binding to these two different targets, Mosunetuzumab is able to redirect the cytotoxic activity of T-cells towards cancerous B-cells. This unique mechanism of action holds great potential for enhancing the effectiveness of cancer treatment.
Cevostamab (BFCR4350A) is an innovative bispecific antibody, designed to engage T-cells and myeloma cells by targeting FcRH5 and CD3 receptors, respectively. Cevostamab possesses a unique structure with two 'Fab' regions, with one specifically targeting FcRH5 and the other targeting CD3. This dual targeting mechanism activates the patient's own T-cells and redirects them to eliminate myeloma cells expressing FcRH5 by releasing cytotoxic proteins.
Synonyms Mosunetuzumab;MOSUNETUZUMAB;Mosunetuzumab-axgb;BTCT-4465A;BTCT 4465A;Lunsumio;RG 7828;RO7030816;Anti-CD20 x Anti-CD3 Bispecific Monoclonal Antibody;
Cevostamab;CEVOSTAMAB;BFCR 4350A; RG 6160; RO 7187797;Anti-FCRH5/CD3 BiTE Antibody

For laboratory research use only. Direct human use, including taking orally and injection and clinical use are forbidden.


feedback

Do you like the current new website?

Hate

Dislike

Neutral

Like

Love

*